Participant’s experiences of taking melatonin for the treatment of nocturia in MS: Qualitative findings from a double blind RCT

Khan, R; Uren, A; Homewood, J; Inglis, K; Johnson, L; Owen, D; Cottrell, D; Drake, M; Cotterill, N

Abstract

Multiple Sclerosis (MS) is a chronic neurological disorder caused by eventual neurodegeneration within the central nervous system resulting in impaired physical, cognitive and psychological functioning. It is often progressive and can result in many unpredictable symptoms, all of which can have a detrimental effect on quality of life(1). Commonly, people with MS will report a number of lower urinary tract symptoms (LUTS) including nocturia (1). This is defined by the International Continence Society (ICS) as the need to ‘wake at night one or more times to void’ (2). Previously, clinical trials have sought to understand the causes of nocturia and have found an association between melatonin secretion and nocturia (3). However, to date, no qualitative studies have been conducted which explore the experience of taking melatonin for the treatment of nocturia within the context of a clinical trial. This study specifically aimed to explore perceptions of this intervention on nocturia and associated quality of life impact from the patients’ perspective.

Citation

Khan, R., Uren, A., Homewood, J., Inglis, K., Johnson, L., Owen, D., …Cotterill, N. (2017, September). Participant’s experiences of taking melatonin for the treatment of nocturia in MS: Qualitative findings from a double blind RCT

• Presentation Conference Type: Speech
• Start Date: Sep 13, 2017
• End Date: Sep 15, 2017
• Acceptance Date: May 10, 2017
• Peer Reviewed: Peer Reviewed
• Keywords: multiple sclerosis, qualitative, patient experience, nocturia, urinary symptoms
• Additional Information: Title of Conference or Conference Proceedings : International Continence Society Annual Meeting 2017